摘要
目的:探讨重组人促红细胞生成素对肾缺血再灌注损伤的作用及机制。方法:实验于2005-07/2006-01在泸州医学院中心实验室和病理生理实验室完成。选择雄性Wistar大鼠54只,建立右肾切除,左肾肾动脉夹闭45min后再灌注的动物模型,将54只大鼠随机数字表法分为左肾未缺血再灌注组18只,切除右肾,不夹闭左肾动脉。重组人促红细胞生成素干预组18只,在再灌注开始前5min静脉注射重组人促红细胞生成素(3000U/kg)。肾缺血再灌注损伤组18只,在再灌注开始前5min注射等量的生理盐水。各组再灌注达1,6,24h时间点检测肾功能(血肌酐,尿素氮),并观察肾组织中丙二醛含量、超氧化物歧化酶活性和组织形态学改变。结果:纳入动物54只,均进入结果分析。①重组人促红细胞生成素干预组肾组织中丙二醛含量与肾缺血再灌注损伤组相比显著降低、超氧化物歧化酶活性显著升高[以再灌注6h为例,分别为(0.93±0.09),(1.19±0.08)μmol/g,(1919.55±126.52),(1338.10±5.50)μkat/g,P<0.05]。②重组人促红细胞生成素干预组血肌酐、尿素氮含量与肾缺血再灌注损伤组相比降低[以再灌注6h为例,分别为(87.53±1.22),(121.63±21.17)μmol/L,(252.06±4.59),(369.14±18.38)mg/L,P<0.05]。③重组人促红细胞生成素干预组肾脏病变与肾缺血再灌注组比较明显减轻,肾小管上皮细胞轻度水肿,基底膜多完整,肾小管腔内见少量管型。结论:重组人促红细胞生成素能减轻肾缺血再灌注损伤,其机制可能是抗氧自由基损伤,提高内源性抗氧化能力。
AIM： To investigate the effects and mechanisms of recombinant human erythropoietin （rHuEPO） on renal ischimia-reperfusion injury.
METHODS; The experiment was performed in Central Laboratory and Pathophysiology Laboratory of Luzhou Medical College from July 2005 to January 2006. Totally 54 male Wistar rats were selected to establish a right-nephrectemized. 45 minutes after interruption of left renal artery blood flow rat models were reperfusd. The 54 Wistar rats were randomly divided into three groups： sham operation group, that was the group of left kidney without ischemia-reperfusion （n = 18）, right-nephrectemized was performed but without occlusion of left renal artery; rHuEPO treatment group （n=18）, rHuEPO was administered intravenously at a dose of 3 000 U/kg 5 minutes before reperfusion; Renal ischemia-reperfusion injury （IRI） group （n=18）, the rats in this group were administered saline equivalently 5 minutes before reperfusion. When it was on the corresponding time of reperfusion at hour 1, 6 and 24, renal function （blood creatine and urea nitrogen） was measured. At the same time, content of malondialdehyde （MDA） and activity of superoxide dismutese （SOD） in kidney tissue were measured, and histopathological damages were observed.
RESULTS： All 54 included rats were involved in the result analysis. （1） Compared with renal IRI group, MDA in kidney tissue was lower significantly, but SOD activity was higher significantly in rHuEPO treatment group （For example, on the time of 6-hour reperfusion, that was （0.93±0.09）, （1.19±0.08） μmol/g, （ 1 919.55±126.52）, （ 1 338.10±5.50） μkat/g, respectively, P 〈 0.05）. （2）Serum levels of blood ereatine and urea nitrogen in rHuEPO treatment group were lower significantly than those in renal IRI group （For example, on the time of 6-hour reperfusion, that was （87.53 ±1.22）, （121.63±21.17） μmol/L, （252.06±4.59）, （369.14±18.38） mg/L respectively, P 〈 0.05）. （3）Compared with renal IRI group, renal histologie injury were obviously attenuated by rHuEPO in rHuEPO treatment group. Renal tubular epithelial cells lightly swelled, basement membrane was mostly integrated. There were few casts in renal tubular.
CONCLUSION： The rHuEPO treatment can attenuate renal ischemia- reperfusion injury, which is probably through preventing oxygen free radicals damage and elevating endogenous antioxidation potential.
出处
《中国临床康复》
CSCD
北大核心
2006年第40期78-80,共3页
Chinese Journal of Clinical Rehabilitation
作者简介
万英★，女，1976年生，四川省自贡市人，汉族，泸州医学院在读硕士，助教，主要从事肾脏病理生理的研究。
通讯作者：李著华，教授，硕士研究生导师，泸州医学院病理生理教研室，四川省泸州市646000
